Humira adalimumab: Phase III data

Data from Period A of the double-blind, international Phase III PIONEER II trial in 326 patients with moderate to severe hidradenitis suppurativa showed that subcutaneous Humira given at 160 mg at week 0, 80 mg at

Read the full 363 word article

How to gain access

Continue reading with a
two-week free trial.